Halozyme Therapeutics (HALO) said Wednesday that Johnson & Johnson (JNJ) unit Janssen-Cilag International received European Commission approval for an indication extension of Darzalex co-formulated with Halozyme's Enhanze drug delivery technology to treat adults newly diagnosed with multiple myeloma.
The latest approval covers people with the disease regardless of transplant eligibility, Halozyme said.
Halozyme's Enhanze drug delivery technology is used for the subcutaneous delivery of injected drugs, the company said.
Halozyme shares were 1% lower in early trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.